Full name
A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma
NCT Number
NCT06372496
Geography
US
Non-US
Locations
Argentina, Australia, Canada, Japan, Republic of Korea, Taiwan, United States,
Primary Endpoints
Change from baseline in trough FEV1 at Week 24
External Link
https://clinicaltrials.gov/study/NCT06372496
Order
3
Disease
Version
Phase
4
Status
Active, not recruiting